Results 11 to 20 of about 1,535,618 (326)

Clinical Outcomes of Treatment of Geographic Atrophy: A Narrative Review [PDF]

Ophthalmology and Therapy
Rationale In 2023, the U.S. Food and Drug Administration approved pegcetacoplan (SYFOVRE) as the first therapeutic option for geographic atrophy (GA), a previously untreatable condition associated with age-related macular degeneration.
Anne Helene Køllund Nissen, Thomas Lee Torp, Anna Stage Vergmann   +2 more
doaj   +2 more sources

Geographic Atrophy in Age-Related Macular Degeneration. [PDF]

Dtsch Arztebl Int
Liakopoulos S, von der Emde L, Biller ML, Ach T, Holz FG.   +4 more
europepmc   +2 more sources

Progression of Geographic Atrophy

Ophthalmology Science, 2023
Purpose: To evaluate disease progression and associated vision changes in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 eye and GA or neovascular AMD (nAMD) in the fellow eye using a large dataset from ...
Ehsan Rahimy, MD, M. Ali Khan, MD, Allen C. Ho, MD, Meghan Hatfield, MPH, Thai Hien Nguyen, MPH, Daniel Jones, PhD, Alex McKeown, MBA, PhD, Durga Borkar, MD, Theodore Leng, MD, Ramiro Ribeiro, MD, PhD, Nancy Holekamp, MD   +10 more
doaj   +1 more source

Compass Fundus-Guided Perimetry in Geographic Atrophy

Journal of Ophthalmology, 2022
Purpose. To evaluate compass (CMP), a recently introduced device that combines scanning ophthalmoscopy, automated perimetry, and eye tracking, for fundus-guided perimetry (microperimetry) with the purpose of correlating perimetric retinal sensitivity ...
Roberta Farci, Arturo Carta, Paolo Fogagnolo, Luca Mario Rossetti, Maurizio Fossarello   +4 more
doaj   +1 more source

αA crystallin may protect against geographic atrophy-meta-analysis of cataract vs. cataract surgery for geographic atrophy and experimental studies. [PDF]

PLoS ONE, 2012
BACKGROUND: Cataract and geographic atrophy (GA, also called advanced "dry" age-related macular degeneration) are the two major causes of visual impairment in the developed world.
Peng Zhou, Hong-Fei Ye, Yong-Xiang Jiang, Jin Yang, Xiang-Jia Zhu, Xing-Huai Sun, Yi Luo, Guo-Rui Dou, Yu-Sheng Wang, Yi Lu   +9 more
doaj   +1 more source

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

Eye, 2023
Background/Objectives To assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over an 18-month treatment course.
Sunil S. Patel, D. Lally, Jason Hsu, C. Wykoff, David A. Eichenbaum, J. Heier, G. Jaffe, K. Westby, Dhaval Desai, Liansheng Zhu, A. Khanani   +10 more
semanticscholar   +1 more source

Geographic atrophy: Mechanism of disease, pathophysiology, and role of the complement system

Journal of Managed Care & Specialty Pharmacy, 2023
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that first start in the outer retina and progressively expand to cover the macula and the fovea, the center of the macula, leading to
S. Bakri, M. Bektas, Darcie A. Sharp, R. Luo, S. Sarda, Shahnaz Khan   +5 more
semanticscholar   +1 more source

Characteristics of geographic atrophy secondary to age-related macular degeneration in Korean patients. [PDF]

BMC Ophthalmol
Park SM, Shin D, Kim CG, Kim JH.
europepmc   +3 more sources

Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration

Clinical Ophthalmology, 2023
Age-related macular degeneration (AMD) is characterized as a chronic, multifactorial disease and is the leading cause of irreversible blindness. Advanced AMD is classified as neovascular (wet) AMD and non-neovascular (dry) AMD.
Hannah Khan, A. Aziz, Humza Sulahria, Huma Khan, Abrahim Ahmed, N. Choudhry, R. Narayanan, Carl J. Danzig, A. Khanani   +8 more
semanticscholar   +1 more source

Therapeutic approaches with intravitreal injections in geographic atrophy secondary to age-related macular degeneration: current drugs and potential molecules [PDF]

, 2019
The present review focuses on recent clinical trials that analyze the efficacy of intravitreal therapeutic agents for the treatment of dry age-related macular degeneration (AMD), such as neuroprotective drugs, and complement inhibitors, also called ...
Cerini, Alberto, Greco A., La Cava M, Lambiase A, Limoli PG, Nebbioso M   +5 more
core   +1 more source